Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments

Haidari, Rana El; Anota, Amélie; Dabakuyo-Yonli, Tienhan Sandrine; Guillemin, Françis; Conroy, Thierry; Velten, Michel; Jolly, Damien; Causeret, Sylvain; Cuisenier, Jean; Graesslin, Olivier; Abou-Abbas, Linda; Nerich, V.

doi:10.1007/s11136-022-03157-4

Cited by 3 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean age across studies was 56.7 years (≥ 70 years in 4 studies [ 27 , 46 , 53 , 57 ]), and the total number of participants was 22,952 (range 30 to 8287). Studies came from the Netherlands [ 31 , 39 – 43 , 59 ], the USA [ 27 , 28 , 37 , 55 , 57 , 60 ], South Korea [ 38 , 44 , 49 , 61 ], Finland [ 51 , 52 , 54 , 65 ], the UK [ 36 , 53 , 62 ], Australia [ 29 , 34 , 63 ], Japan [ 33 , 58 ], Spain [ 45 , 47 ], Norway [ 48 ], Italy [ 50 ], Croatia [ 64 ], Thailand [ 56 ], France [ 35 ], Greece [ 32 ], England and Wales [ 46 ], and multiple countries (UK, USA, Japan, France, Germany, Italy, and Spain) [ 30 ]. Other demographic information including race/ethnicity, comorbidities, and family history was scarce and not consistently reported.…”

Section: Resultsmentioning

confidence: 99%

“… Disutility of false-positive result requiring imaging plus biopsy N = 1 study [ 32 ] N = 78 participants ⊕⊝⊝⊝ VERY LOW a,b,d We are very uncertain about the disutility of a false positive result after invasive testing. Disutility of a true-positive result, before treatment N = 9 studies [ 31 , 35 , 44 – 46 , 52 , 53 , 61 , 64 ] N = 6657 participants Direct methods: N = 1 [ 53 ] SG, n = 156 ⊕⊕⊕⊝ MODERATE b,c The disutility of a screen-detected cancer is probably on average 0.08, but may be higher for older ages and advanced stage operable cancer. Disutility of an interval cancer N = 1 study (using VAS) [ 28 ] N = 131 participants ⊕⊕⊝⊝ LOW a,b,d The disutility for interval cancer may be similar to a screen-detected cancer.…”

Section: Resultsmentioning

confidence: 99%

“…The disutility of a true-positive result (screen-detected cancer) is probably on average 0.08, but may be higher for older ages and advanced stage operable breast cancer [ 31 , 35 , 44 – 46 , 52 , 53 , 61 , 64 ]. Removing two studies at high risk of bias did not impact the findings.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care

Pillay,

Guitard,

Rahman

et al. 2024

Syst Rev

View full text Add to dashboard Cite

Background Different guideline panels, and individuals, may make different decisions based in part on their preferences. Preferences for or against an intervention are viewed as a consequence of the relative importance people place on the expected or experienced health outcomes it incurs. These findings can then be considered as patient input when balancing effect estimates on benefits and harms reported by empirical evidence on the clinical effectiveness of screening programs. This systematic review update examined the relative importance placed by patients on the potential benefits and harms of mammography-based breast cancer screening to inform an update to the 2018 Canadian Task Force on Preventive Health Care's guideline on screening. Methods We screened all articles from our previous review (search December 2017) and updated our searches to June 19, 2023 in MEDLINE, PsycINFO, and CINAHL. We also screened grey literature, submissions by stakeholders, and reference lists. The target population was cisgender women and other adults assigned female at birth (including transgender men and nonbinary persons) aged ≥ 35 years and at average or moderately increased risk for breast cancer. Studies of patients with breast cancer were eligible for health-state utility data for relevant outcomes. We sought three types of data, directly through (i) disutilities of screening and curative treatment health states (measuring the impact of the outcome on one’s health-related quality of life; utilities measured on a scale of 0 [death] to 1 [perfect health]), and (ii) other preference-based data, such as outcome trade-offs, and indirectly through (iii) the relative importance of benefits versus harms inferred from attitudes, intentions, and behaviors towards screening among patients provided with estimates of the magnitudes of benefit(s) and harms(s). For screening, we used machine learning as one of the reviewers after at least 50% of studies had been reviewed in duplicate by humans; full-text selection used independent review by two humans. Data extraction and risk of bias assessments used a single reviewer with verification. Our main analysis for utilities used data from utility-based health-related quality of life tools (e.g., EQ-5D) in patients; a disutility value of about 0.04 can be considered a minimally important value for the Canadian public. When suitable, we pooled utilities and explored heterogeneity. Disutilities were calculated for screening health states and between different treatment states. Non-utility data were grouped into categories, based on outcomes compared (e.g. for trade-off data), participant age, and our judgements of the net benefit of screening portrayed by the studies. Thereafter, we compared and contrasted findings while considering sample sizes, risk of bias, subgroup findings and data on knowledge scores, and created summary statements for each data set. Certainty assessments followed GRADE guidance for patient preferences and used consensus among at least two reviewers. Findings Eighty-two studies (38 on utilities) were included. The estimated disutilities were 0.07 for a positive screening result (moderate certainty), 0.03–0.04 for a false positive (FP; “additional testing” resolved as negative for cancer) (low certainty), and 0.08 for untreated screen-detected cancer (moderate certainty) or (low certainty) an interval cancer. At ≤12 months, disutilities of mastectomy (vs. breast-conserving therapy), chemotherapy (vs. none) (low certainty), and radiation therapy (vs. none) (moderate certainty) were 0.02–0.03, 0.02–0.04, and little-to-none, respectively, though in each case findings were somewhat limited in their applicability. Over the longer term, there was moderate certainty for little-to-no disutility from mastectomy versus breast-conserving surgery/lumpectomy with radiation and from radiation. There was moderate certainty that a majority (>50%) and possibly a large majority (>75%) of women probably accept up to six cases of overdiagnosis to prevent one breast-cancer death; there was some uncertainty because of an indication that overdiagnosis was not fully understood by participants in some cases. Low certainty evidence suggested that a large majority may accept that screening may reduce breast-cancer but not all-cause mortality, at least when presented with relatively high rates of breast-cancer mortality reductions (n = 2; 2 and 5 fewer per 1000 screened), and at least a majority accept that to prevent one breast-cancer death at least a few hundred patients will receive a FP result and 10–15 will have a FP resolved through biopsy. An upper limit for an acceptable number of FPs was not evaluated. When using data from studies assessing attitudes, intentions, and screening behaviors, across all age groups but most evident for women in their 40s, preferences reduced as the net benefit presented by study authors decreased in magnitude. In a relatively low net-benefit scenario, a majority of patients in their 40s may not weigh the benefits as greater than the harms from screening whereas for women in their 50s a large majority may prefer screening (low certainty evidence for both ages). There was moderate certainty that a large majority of women 50 years of age and 50 to 69 years of age, who have usually experienced screening, weigh the benefits as greater than the harms from screening in a high net-benefit scenario. A large majority of patients aged 70–71 years who have recently screened probably think the benefits outweigh the harms of continuing to screen. A majority of women in their mid-70s to early 80s may prefer to continue screening. Conclusions Evidence across a range of data sources on how informed patients value the potential outcomes from breast-cancer screening will be useful during decision-making for recommendations. The evidence suggests that all of the outcomes examined have importance to women of any age, that there is at least some and possibly substantial (among those in their 40s) variability across and within age groups about the acceptable magnitude of effects across outcomes, and that provision of easily understandable information on the likelihood of the outcomes may be necessary to enable informed decision making. Although studies came from a wide range of countries, there were limited data from Canada and about whether findings applied well across an ethnographically and socioeconomically diverse population. Systematic review registration Protocol available at Open Science Framework https://osf.io/xngsu/.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care

Pillay,

Guitard,

Rahman

et al. 2024

Syst Rev

View full text Add to dashboard Cite

show abstract

“…The mean age across studies was 56.7 years (≥ 70 years in 4 studies [25,44,51,55]), and the total number of participants was 22,952 (range 30 to 8,287). Studies came from the Netherlands [29,[37][38][39][40][41]57], USA [25,26,35,53,55,58], South Korea [36,42,47,59], Finland [49,50,52,63], the United Kingdom [34,51,60], Australia [27,32,61], Japan [31,56], Spain [43,45], Norway [46], Italy [48], Croatia [62], Thailand [54], France [33], Greece [30], England…”

Section: Study Characteristicsmentioning

confidence: 99%

“…South Korea [36,42,47,59], Finland [49,50,52,63], the United Kingdom [34,51,60], Australia [27,32,61], Japan [31,56], Spain [43,45], Norway [46], Italy [48], Croatia [62], Thailand [54], France [33], Greece [30],…”

Section: Study Characteristicsmentioning

confidence: 99%

Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care

Pillay,

Guitard,

Rahman

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Different guideline panels, and individuals, may make different decisions based in part by their preferences. This systematic review update examined the relative importance placed by patients aged ≥ 35 years on the potential outcomes of breast-cancer screening. Methods We updated our searches to June 19, 2023 in MEDLINE, PsycINFO, and CINAHL. We screened grey literature, submissions by stakeholders, and reference lists. We sought three types of preferences, directly through i) utilities of screening and curative treatment health states (measuring the impact of the outcome on one’s health-related quality of life), and ii) other preference-based data, such as outcome trade-offs, and indirectly through iii) the relative importance of benefits versus harms inferred from attitudes, intentions, and behaviors towards screening among informed patients. For screening we used machine learning as one of the reviewers after at least 50% of studies had been reviewed in duplicate by humans; full-text selection used independent review by two humans. Data extraction and risk of bias assessments used a single reviewer with verification. Our main analysis for utilities used data from utility-based health-related quality of life tools (e.g., EQ-5D) in patients. When suitable, we pooled utilities and explored heterogeneity. Disutilities were calculated for screening health states and between different treatment states. Non-utility data were grouped into categories and synthesized with creation of summary statements. Certainty assessments followed GRADE guidance. Findings Eighty-two studies (38 on utilities) were included. The estimated disutilities were 0.07 for a positive screening result (moderate certainty), 0.03-0.04 for a false positive (FP; “additional testing” resolved as negative for cancer) (low certainty), and 0.08 for untreated screen-detected cancer (moderate certainty) or (low certainty) an interval cancer. At ≤12 months, disutilities of mastectomy (vs. breast-conserving therapy), chemotherapy (vs. none) (low certainty), and radiation therapy (vs. none) (moderate certainty) were 0.02-0.03, 0.02-0.04, and little-to-none, respectively. Over the longer term, there was moderate certainty for little-to-no disutility from mastectomy versus breast-conserving surgery/lumpectomy with radiation and from radiation. There was moderate certainty that a majority (>50%) and possibly large majority (>75%) of women probably accept up to six cases of overdiagnosis to prevent one breast-cancer death.Low certainty evidence suggested that a large majority may accept that screening may reduce breast-cancer but not all-cause mortality, at least when presented with relatively high rates of breast-cancer mortality reductions (n=2; 2 and 5 fewer per 1000 screened), and at least a majority accept that to prevent one breast-cancer death at least a few hundred patients will receive a FP result and 10-15 will have a FP resolved through biopsy. When using data from studies assessing attitudes, intentions, and screening behaviors, across all age groups but most evident for women in their 40s, preferences reduced as the net benefit presented by study authors decreased in magnitude. In a relatively low net-benefit scenario, a majority of patients in their 40s may not weigh the benefits as greater than the harms from screening (low certainty evidence). A large majority of patients aged 70-71 years probably think the benefits outweigh the harms for continuing to screen. A majority of women in their mid-70s to early 80s may prefer to continue screening. Conclusions Evidence across a range of data sources on how informed patients value the potential outcomes from breast-cancer screening will be useful during decision-making for recommendations. Further, the evidence supports providing easily understandable information on possible magnitudes of effects to enable informed decision-making. Systematic review registration: Protocol available at Open Science Framework https://osf.io/xngsu/

show abstract

Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis

Tanaka,

Yasuda,

Tachi

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Chemotherapy has helped prolong survival in patients with malignant lymphoma, enhancing their quality of life (QOL). Despite the eventual decline in the QOL of patients, the impact of initial chemotherapy remains poorly understood. A prospective patient-reported QOL survey among patients with malignant lymphoma receiving initial chemotherapy was conducted, targeting those treated at Gifu Municipal Hospital (Gifu, Japan) between January 2021 and December 2022. Surveys were conducted pre- and post-chemotherapy based on the EuroQol 5 dimensions. Drug costs were calculated using official prices and analyzed from the cost payer's perspective via cost-utility analysis. Among the 60 patients included in the present study, 28 had diffuse large B-cell lymphoma. Cyclophosphamide, doxorubicin, vincristine, prednisolone ± rituximab therapy was the most common treatment (38 patients) and demonstrated superior cost-effectiveness due to its lowest cost and change in utility value. Initial chemotherapy for patients with malignant lymphoma generally improved the QOL. Clinical trial registration: UMIN000042868 (registered on December 28, 2020).

show abstract

Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments

Cited by 3 publications

References 42 publications

Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care

Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care

Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care

Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis

Contact Info

Product

Resources

About